@article{article, title  = {{PD37-09 THE FIRST REPORT OF DISEASE-FREE SURVIVAL ANALYSES FROM THE NIAGARA TRIAL OF PERIOPERATIVE DURVALUMAB PLUS NEOADJUVANT CHEMOTHERAPY IN MUSCLE-INVASIVE BLADDER CANCER}},

 publisher = {{Ovid Technologies (Wolters Kluwer Health)}},

 url = {{https://doi.org/10.1097/01.ju.0001110188.58981.bc.09 }},

 year = {{2025}},

 month = {{5}},

 author = {{Meeks JJ and van der Heijden MS and Powles T and Galsky MD and Al-Ahmadie H and Nishiyama H and Drakaki A and Vu TQ and Antonuzzo L and Wiechno P and Atduev V et al}},

 doi = {{10.1097/01.ju.0001110188.58981.bc.09}},

 volume = {{213}},

 journal = {{Journal of Urology}},

 issue = {{5S}},

 note = {{Accessed on 2025/06/09}}}